When it comes to the US FDA's complex innovative trial design pilot, it's unclear which will be more intricate: the new development pathways formed through the program, or the negotiations with the agency before a sponsor can even join.
FDA will require details of the trials used in the program to be released for the benefit of the drug industry at large. The agency now is hoping it will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?